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Abstract
Background: Small trials have suggested that fluoxetine may improve neurological recovery from stroke. FOCUS,
AFFINITY and EFFECTS are a family of investigator-led, multicentre, parallel group, randomised, placebo-controlled
trials which aim to determine whether the routine administration of fluoxetine (20 mg daily) for six months after an
acute stroke improves patients’ functional outcome.
Methods/Design: The core protocol for the three trials has been published (Mead et al., Trials 20:369, 2015). The
trials include patients aged 18 years and older with a clinical diagnosis of stroke and persisting focal neurological
deficits at randomisation 2–15 days after stroke onset. Patients are randomised centrally via each trials’ web-based
randomisation system using a common minimisation algorithm. Patients are allocated fluoxetine 20 mg once daily
or matching placebo capsules for six months. The primary outcome measure is the modified Rankin scale (mRS) at
six months. Secondary outcomes include: living circumstances; the Stroke Impact Scale; EuroQol (EQ5D-5 L); the vitality
subscale of the 36-Item Short Form Health Survey (SF36); diagnosis of depression; adherence to medication; serious
adverse events including death and recurrent stroke; and resource use at six and 12 months and the mRS at
12 months.
Discussion: Minor variations have been tailored to the national setting in the UK (FOCUS), Australia, New Zealand and
Vietnam (AFFINITY) and Sweden (EFFECTS). Each trial is run and funded independently and will report its own results. A
prospectively planned individual patient data meta-analysis of all three trials will provide the most precise estimate of
the overall effect and establish whether any effects differ between trials or subgroups. This statistical analysis plan
describes the core analyses for all three trials and that for the individual patient data meta-analysis. Recruitment and
follow-up in the FOCUS trial is expected to be completed by the end of 2018. AFFINITY and EFFECTS are likely to
complete follow-up in 2020.
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Introduction
Small trials have suggested that fluoxetine may improve
neurological recovery from stroke [1]. FOCUS, AFFINITY
and EFFECTS are a family of investigator-led, multicentre,
parallel group, randomised, placebo-controlled trials which
aim to determine whether the routine administration of
fluoxetine (20 mg daily) for six months after an acute
stroke improves patients’ functional outcome.
A description of the FOCUS, AFFINITY and EFFECTS
core protocol has already been published [1] and that art-
icle contained a brief description of planned analyses.
However, to avoid any misunderstanding that our final
analyses could be post hoc or data-driven, we have pub-
lished this more detailed statistical analysis plan in advance
of completing recruitment. The first draft was prepared by
CG and SL before any unblinding to data (see Additional
file 1); subsequent drafts were written without input from
CG who performed the interim analyses for the FOCUS
trial DMC.
Before describing the planned final analyses, the key
objectives and methodological features of the three trials
are presented.
Objectives of the individual trials and the prospectively
planned individual patient data meta-analysis
We have collaboratively designed and implemented a
family of three large, investigator-led, government and
charity-funded, multicentre, placebo-controlled rando-
mised trials which together aim to robustly address sev-
eral research questions.
Our main objective is to determine whether the routine
administration of fluoxetine 20 mg daily started 2–15 days
post stroke, and continued for six months, improves
recovery, and whether any benefits persist after the treat-
ment has stopped, until 12 months after the stroke. The
other research questions have been described previously
and are included in this analysis plan along with a descrip-
tion of the analyses aimed at addressing each of the
questions.
The trials are powered to detect differences in the pri-
mary outcome based on an ordinal analysis of the seven
categories of the modified Rankin scale (mRS 0, 1, 2, 3,
4, 5, 6) [2]. Because it is not feasible to enrol sufficient
patients in each trial to reliably detect small, yet clinic-
ally important, effects of fluoxetine, we plan to perform
an individual patient data meta-analysis including the
data from FOCUS, AFFINITY and EFFECTS.
Patient population
Patients are identified by participating clinicians from in-
patient stroke services and outpatient clinics in UK
(FOCUS), Australasia, New Zealand and Vietnam
(AFFINITY) and Sweden (EFFECTS). The full inclusion
and exclusion criteria have already been published [1].
Randomisation
Having obtained consent, the randomising person enters
the baseline data into a trial-specific computerised cen-
tral randomisation service by means of a secure 24/7
Web interface. After the computer program has checked
these baseline data for completeness and internal
consistency, it allocates that patient a unique study iden-
tification number and a treatment pack number which
corresponds to either fluoxetine or placebo. The trial-
specific systems apply a common minimisation program
to achieve balance for four factors [3]:
 delay since stroke onset (2–8 vs 9–15 days);
 predicted six-month outcome based on the six simple
variable (SSV) model [4];
 presence of a motor deficit based on the National
Institute of Health Stroke Scale (NIHSS) [5];
 presence of aphasia (based on NIHSS).
The SSV model [4] includes:
1. patient’s age;
2. whether independent in activities of daily living
before the stroke;
3. whether living alone before the stroke;
4. whether able to lift both arms off the bed;
5. whether able to walk without the help of another
person;
6. whether able to talk, and not confused.
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The NIHSS is a 15-item questionnaire where responses
to each question are assigned a score in the range of 0–4
(some questions are scored 0–2 or 0–3 as appropriate).
The total score is calculated by summing across all
questions.
Sample size
FOCUS, AFFINITY and EFFECTS are planned to enrol
at least 3000, 1600 and 1500 patients, respectively. These
numbers would provide 90% power with an alpha of
0.05, based on the distribution of outcomes in the seven
categories of the mRS (0–6) observed in both treatment
groups combined among the first 451 patients enrolled
and followed up at six months in the FOCUS trial. If
FOCUS, AFFINITY and EFFECTS combined enrol 6000,
we would have 90% power (alpha 5%) to detect a com-
mon odds ratio (COR) of 1.16, equivalent to a 3.7% ab-
solute difference in percentage with mRS 0–2 (44.0% to
47.7%). The trial steering committees (TSC) will regu-
larly review the target sample size and adjust this based
on accruing blinded data.
Blinding
The patient, their families, the healthcare team—in-
cluding the pharmacist—and anyone involved in out-
patient assessments are blinded to the treatment
allocation. Emergency unblinding systems are available
for each trial.
Follow-up
Early follow-up, during the index admission and in the
first month to identify adverse events and monitor
adherence is carried out by the local centres in all three
trials. However, each trial’s national coordinating centres
aim to follow-up the patients at about six and 12 months
with postal and telephone questionnaires to measure the
primary and secondary outcomes. However, the trials
vary in the timing, frequency and method of monitoring
the patients’ progress. Data are also collected from
general practitioners and by data linkage to mortality
and hospital admission data in all three trials. The
reasons why patients stopped taking the trial medication
are recorded.
Primary outcome
The primary outcome is functional status, measured
with the mRS [2] at the six-month follow-up. We are
using the simple modified Rankin scale questionnaire
(smRSq) delivered by postal questionnaire or via inter-
view over the telephone or face-to-face to determine the
mRS [6–8]. The smRSq is based on the yes/no responses
to five questions [7].
Secondary outcomes
1. Survival till the end of the trial. This is determined
by following patients up for 12 months through
their GPs and telephone and postal questionnaire
and thereafter through linkage to routine mortality
data.
2. Functional status (mRS) at 12-month follow-up.
3. Health status with the Stroke Impact Scale (SIS)
comprising 59 questions divided into nine domains
on each of which the patient scores 0–100 [9–11].
The domains cover:
a. Arm, hand, leg and foot strength;
b. Hand function;
c. Mobility;
d. Daily activities;
e. Communication and understanding;
f. Memory and thinking;
g. Mood and emotions;
h. Participation in work, leisure and social activities;
i. Recovery rated on a vertical visual analogue scale
(VAS; 0–100).
The domain scores are derived using the formula [9]:
Transformedscale ¼ ½ raw score–lowestpossible raw scoreð Þ
=possible raw score range  100
4. Adverse events/outcomes:
a. depression. A new diagnosis and/or treatment of
depression during follow-up. Participants (or a
proxy or GP) are asked if they have been diagnosed
with new depression since their last assessment,
whether this has been treated and whether they
have been started on an antidepressant medication;
b. recurrent stroke including ischaemic and
haemorrhagic strokes;
c. acute coronary syndromes;
d. epileptic seizures;
e. episodes of hyponatraemia (< 125 mmol/L);
f. upper gastrointestinal (GI) bleeding;
g. other major bleeds (lower GI, extracranial,
intracranial but extracerebral);
h. poorly controlled diabetes including
hyperglycaemia (> 22 mmol/L) and symptomatic
hypoglycaemia;
i. falls resulting in injury;
j. new bone fractures;
k. attempted suicide/self-harm.
5. Fatigue (Vitality subscale of the 36-Item Short Form
Health Survey [SF36]) [12, 13]. In the full SF36, the
vitality questions are 9a, 9e, 9 g, 9i. For a and e,
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these are scored 5 points for ‘all of the time’ through
to 1 point for ‘none of the time’ while g and i are
scored 1 point for ‘all of the time’ through to 5
points for ‘none of the time’. A raw score is then
calculated by summing across the four questions,
resulting in a score of 4–20 with a range of 16. The
raw scores are then transformed to a score in the
range of 0–100 using the formula:
Transformed scale = [(raw score – lowest possible
raw score)/possible raw score range] * 100 [14].
6. Cognition. The SIS which incorporates an assessment
of memory and thinking is used for all three trials
[9–11]. In AFFINITY, cognition during follow-up is
assessed with the Modified Telephone Interview for
Cognitive Status (TICSm) [15]. EFFECTS assesses
cognition with the Montreal Cognitive Assessment
(MoCA) at baseline and six months (face-to-face) [16].
Only the analysis of the SIS is described.
7. Mood. The individual trials used different scales to
compare the mood of patients at follow-up using:
Mental Health Inventory 5 (MHI) in FOCUS [17];
PHQ9 in AFFINITY [18]; and MADRS in
EFFECTS [19].
8. Health-related quality of life measured with the
five-level Euroqol (EQ5D-5L) to generate utilities
based on population preferences [20, 21].
The EQ5D-5L consists of five dimensions, each with five
levels of perceived problems: Level 1 = no problem; Level 2
= slight problems; Level 3 =moderate problems; Level 4 =
severe problems; Level 5 = extreme problems/unable to
perform. Each level is assigned a numerical code (level 1 =
code 1, level 2 = code 2, etc.). These dimensions are
combined to give a five-digit code with any missing dimen-
sion coded as ‘9’. Each health state is assigned a single
index-based numerical value (‘utility’) that can be combined
with survival times to generate quality-adjusted life years
(QALYs). Initially we will use the largest and most recent
EQ-5D-5 L value set calibrated for an English population
[21] but will apply corresponding population specific value
sets as they appear for the centres/countries participating
in this family of trials (https://euroqol.org/eq-5d-instru-
ments/eq-5d-5l-about/).
Each trial is collecting data about resource use over the
first 12 months to enable us to carry out health economic
analyses; these will be trial-specific but a combined analysis
will be undertaken including data common to all
three trials.
Statistical analysis plan
We will present a CONSORT diagram and a table of
baseline data (see Table 1) but will not carry out any
testing of statistical significance of difference between
treatment groups unless required by the publishing
journal [22]. For all analyses, unless otherwise specified,
we will retain participants in the treatment group to
which they were originally assigned, irrespective of the
treatment they actually received (i.e. an intention-to-treat
analysis).
The final analyses will be performed after the final pa-
tient has been recruited and followed up for a minimum
of 12 months post randomisation. The final analyses will
be performed on the dataset after any ‘cleaning’ that may
be required has been completed and the database locked.
The treatment allocation will only then be unblinded.
The primary analysis will be programmed by CG and
also independently by a second statistician and the re-
sults will be compared; any inconsistencies will be
Table 1 Baseline data collected before randomisation in the
three trials
Data item Fluoxetine Placebo
Age (years (mean, SD))
Gender (male %)
Ethnicity
Marital status
Living arrangements
Employment
Independent in everyday activities before
the stroke
Patient consented for themselves
Co-morbidities (existing)
Previous ischaemic stroke/TIA
Previous intracranial bleeding
Known coronary heart disease
Current depression
Past depression
Known diabetes mellitus
Previous upper gastrointestinal bleeding
Current or past hyponatraemia (Na < 130 mmol/L)
Previous bone fractures
Status at enrolment
NIHSS (median, IQR)
Motor deficit present on NIHSS
Aphasia present on NIHSS
Ability to lift both arms
Ability to walk alone
Able to talk and not confused (GCS speech
normal)
Patient health questionnaire (PHQ)
Haemorrhage on brain imaging?
OCSP classification for ischaemic stroke
Modified TOAST classification
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identified and resolved by discussion. The rest of the
analysis report will be scrutinised for unexpected
findings and checked for accuracy.
A statistical significance level of p < 0.05 (two-tailed) will
be applied to all analyses. All adjusted analyses will be
adjusted for the variables included in our minimisation
algorithm with presence of motor deficit and aphasia as
binary variables as defined above but including delay since
stroke onset (days) and predicted probability of a good
outcome at six months as continuous variables.
Primary analysis
This aims to address our primary research question:
does the routine administration of fluoxetine (20 mg
o.d.) for six months after an acute stroke improve
patients’ functional status at six months?
To minimise missing data, our analyses of the primary
outcome will include a mRS obtained between 90 days
and one year after randomisation, taking the value
measured closest to the six-month time point. The
distribution of delays from randomisation to this follow-
up will be presented to ensure it does not differ between
treatment groups.
We will present the number and percent of patients in
each treatment group by mRS category. In our compari-
son of mRS at six months post randomisation by treat-
ment group, the mRS will be treated in its full ordinal
format (scores of 0, 1, 2, 3, 4, 5, 6) [23]. This will be
examined using an ordinal logistic regression and will be
performed in both an unadjusted manner and also
adjusted for factors in the baseline minimisation. The
latter will be our primary estimate of treatment effect as
recommended by the Medicines and Healthcare prod-
ucts Regulatory Agency (UK). We will present common
odds ratios (ORs) with 95% confidence intervals (CI)
using the proportional odds method and for the
unadjusted analysis we will also present the individual
dichotomies. We will calculate absolute reductions in
risk from these values along with 95% CIs. We will give
a p value. In addition, the results will be presented as
relative risks with 95% CI, calculated from the OR [24]
and absolute risk differences with 95% CI.
Secondary analyses
Analyses of secondary outcomes and analysis of our pri-
mary outcome (ordinal mRS) in pre-defined subgroups
will be performed to address the other research ques-
tions listed in our protocol. Where the outcome of inter-
est is binary, comparison by treatment group will be
examined using a binary logistic regression and will be
adjusted for factors used in the minimisation algorithm.
These will be presented as ORs and 95% CIs, absolute
risk reductions with 95% CI and relative risks using the
same method as for the primary outcome. Unadjusted
ORs and 95% CIs will also be presented.
Where the outcome of interest is continuous, descrip-
tive statistics will be presented (N, mean, sd, min, max,
median, Q1, Q3) categorised by allocated treatment.
Due to the nature of the distribution of these measures
in this population, a simple unadjusted analysis will be
performed comparing the two treatment groups using a
Mann–Whitney test (i.e. not adjusted for variables in the
minimisation algorithm). If the data are not of the re-
quired form (for instance if ≥ 75% of respondents have
the same value), we will use another suitable method.
This analysis will be conducted for the following out-
comes at both six and 12 months:
1. Fatigue measured by the vitality sub-scale of the
SF36.
2. Individual SIS Domain scores, a ‘Motor score’
derived from averaging scores across three domains
(Arm, hand, leg and foot strength; Hand function;
and Mobility), a ‘Physical function score’ derived by
averaging across four domains (Arm, hand, leg and
foot strength; Hand function; Mobility; and Daily
activities) and Recovery based on the VAS.
3. Cognition will be compared between the placebo
and fluoxetine groups using the SIS domain Memory
and thinking in all trials, and in individual trials
using the TICs-M (AFFINITY) and MOCA
(EFFECTS).
4. Mood will be compared between the placebo and
fluoxetine groups in all trials with the Mood and
emotions domain of the SIS, and in individual trials
using MHI [17] in FOCUS, PHQ9 [18] in AFFINITY
and MADRS [19] in EFFECTS.
5. Quality of life as measured by the EQ5D-5L.
Our analyses aim to answer the following questions:
1. If fluoxetine improves functional status (mRS) at six
months, does any improvement in functional status
persist after treatment is stopped? To answer this
question, we will use ordinal regression to compare
functional status (mRS scores) at the 12-month
follow-up, as for our primary analysis.
2. Does fluoxetine influence the secondary outcome
measures (living circumstances, quality of life,
fatigue, stroke impact and mood) at six months
and/or 12 months? The binary outcomes are:
living at home or with relative vs care home;
hospital or long-term care; mRS at six months
and 12 months (mRS 0–2 vs mRS 3–6); new
diagnosis of depression corroborated by the GP or
hospital after randomisation by six months and
12 months. The continuous outcomes are
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EQ5D-5L, Vitality subscale of SF36, SIS, MHI5,
PHQ9 and MADRS.
3. Does fluoxetine increase the risk of serious adverse
events? We will compare the proportion of patients
having any of the following adverse events (all binary
outcomes) between randomisation and cessation of
the trial medication (i.e. investigational medicinal
product), based on treatment received rather than
intention to treat:
a. any recurrent stroke;
b. ischaemic stroke (not TIAs);
c. haemorrhagic stroke;
d. acute coronary syndromes;
e. epileptic seizure;
f. episode of hyponatraemia (< 125 mmol/L);
g. upper gastrointestinal bleeding;
h. other major bleeds (lower GI, extracranial,
intracranial but extracerebral);
i. poorly controlled diabetes including
hyperglycaemia (> 22 mmol/L) or symptomatic
hypoglycaemia;
j. falls resulting in injury;
k. new fractures;
l. attempted suicide/self-harm.
4. If fluoxetine is effective, is it also cost-effective? Each
trial has taken slightly different approaches to the
estimating the cost-effectiveness of the interventions.
These have been tailored to their national
circumstances. We envisage performing an individual
patient data meta-analysis to derive the best estimate
of overall cost-effectiveness and that in subgroups of
patients. At this stage when it is unclear which data
will be available in which trials, we cannot be too
specific about the statistical methods to be used.
We plan to carry out within-trial economic analysis
of direct resource costs and health outcomes on an
intention-to-treat basis. A health service perspective
will be adopted for measuring and valuing health
service use over a 12-month time horizon, although
some data to reflect indirect costs will be available in
the EFFECTS trial (Sweden).
We will estimate cumulative costs of inpatient
episodes, hospital outpatient visits, care home stays
and home care visits. Unit costs will be obtained
from each participating country (Australia, New
Zealand and Vietnam, Sweden and the United
Kingdom) and applied to patient-level data collected
within each international setting.
The number and duration of hospital episodes and
other secondary care contacts will be recorded using
linkage to routine data or information obtained from
the case report form. Resource use will be valued
using unit costs taken from national datasets and
published sources (e.g. Australian National Hospital
Cost Data Collection, UK Unit Costs of Health and
Social Care, Swedish National Cost per Patient
register). Unit prices will be applied to resource use
data using 2018 as the reference year with
country-specific health-sector price deflators used to
adjust costs reported in other years. No discounting of
direct resource costs will be conducted as the time
horizon will be limited to 12 months for within-trial
analysis. Output-based hospital-specific purchasing
power parities (PPPs) will be used for conversion of
expenditure estimates using a common (currency) unit.
Self-reported health-related quality of life (HRQoL)
at six and 12 months of follow-up will be measured
using the EQ-5D-5 L preference based scale.
EQ-5D-5 L single index values will be calculated
using English value sets updated if value sets are
reported for other countries where the family of
trials are being conducted. We also plan to validate
the EQ-5D-5 L by checking the concordance with
the mRS.
A standard multiplicative model will be used to
estimate QALYs calculated by the area under linear
interpolation of the EQ-5D-5 L index trajectory for
each individual with survival times, the EQ-5D-5 L
utility index score at six and 12 months, and a
modelled baseline EQ-5D-5 L utility index value.
Multiple imputation with chained equations will be
used to impute missing HRQoL data on the
EQ-5D-5 L assuming missing at random [25]. We
will perform sensitivity analysis based on cases with
complete data follow-up and examine whether the
pattern of missingness is informative with respect to
key individual characteristics.
The primary treatment effect in the economic
analysis will be estimated using an individual level
regression model for average (mean) incremental
costs and incremental QALY times over 12 months
after randomisation. The model will consider the
joint distribution of costs and QALYs using a
general specification that will allow for different
parametric and conditional distributions. We also
plan to use a Bayesian model with minimally
informative priors for means and large variances
[26]. Model parameter uncertainty will be addressed
using probabilistic sensitivity analysis summarised
using the cost-effectiveness acceptability curve. We
will also conduct a companion analysis of
cost-effectiveness where we will truncate the
cumulative cost distribution at six months and
estimate the incremental costs in relation to
incremental differences in the primary outcome
measure (mRS at six months).
Secondary analyses will be conducted to address
heterogeneous treatment effects. Subpopulations
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with different average treatment effects will be
identified using ‘regression tree’ or ‘recursive
partitioning’ methods [27]. These data-driven
analyses will complement pre-specified subgroup
analyses examining individual and group covariates
of substantive interest such as stroke severity
(NIHSS) and the SSV model for prognosis [4].
Longer run modelling will estimate the distribution
of costs and QALYs calculated over the expected
patient lifetimes. A microsimulation model will be
calibrated using information gained from the within
trial analysis of cost-effectiveness combined with
additional data from: (1) trials and observational
studies reporting longer run costs, survival and
HRQoL following stroke; and (2) expert beliefs on
the distributions of parameters where information is
less readily available. The structural uncertainty in
the long run model will be addressed using model
averaging methods.
The design of the economic analysis will contribute
to a structured overview of treatment effects taking
advantage of the common trial protocols and
consistent capture of resource use and outcomes in
FOCUS, AFFINITY and EFFECTS. Generalisability
and, in particular, the assessment of treatment effect
heterogeneity will be enhanced by the pooled data
across these trials.
5. Is fluoxetine associated with longer-term survival?
Functional outcome at six months post stroke is
strongly associated with long-term survival and so we
wish to determine whether any benefits on functional
outcome would translate into longer-term survival
[28]. We will use Cox proportional hazards regression
to analyse the effect of treatment on survival to
12 months. We will adjust for the variables included
in our minimisation algorithm.We will present this
analysis graphically (cumulative hazard of death [%] vs
time), providing a hazard ratio with 95% CIs and a p
value. This analysis will be repeated if survival data for
a more prolonged period becomes available and
sufficient resources are available to perform and
report the analyses.
6. Does the presence or absence of any of the following
factors materially alter the effect of fluoxetine on our
primary outcome:
a. stroke pathology (ischaemic vs haemorrhagic vs
uncertain pathological type);
b. age (≤ 70 years, > 70 years);
c. stroke severity, i.e. baseline probability of a good
outcome on mRS calculated with the SSV model
[4] to see if effects remain constant across the
range of stroke severities (< 0.15 vs 0.15–1);
d. patients who were unable to consent for
themselves, since this subgroup will allow us to
address the question whether routine use of
fluoxetine is likely to benefit patients in whom a
formal assessment of mood is impossible because
of communication and cognitive problems;
e. inability to assess mood because of
communication or cognitive problems (NIHSS
Q1b > 0 or Q1c > 0 or Q9 > 1 or Unable to
answer PHQ2 [29] at randomisation). Defining
the patients’ ability to have their baseline mood
assessed based on NIHSS and PHQ is likely to be
more meaningful than based on patient or proxy
consent (see d above), especially since no proxy
consent is allowed in EFFECTS (Sweden);
f. patients with and without depression at baseline.
Depression at baseline is defined as ‘Current
depression at baseline’ or answers yes to both
questions in PHQ2, because the systematic review
[30] suggested that the effect of selective
serotonin reuptake inhibitors (SSRI) was greater
in those who were depressed.
The functional status (mRS) at six months will be
compared with ordinal regression in these mutually
exclusive subgroups by entering a treatment by
subgroup interaction into the regression model.
7. In patients with motor deficits at randomisation, does
fluoxetine improve motor function? Patients with a
motor deficit affecting the face/arm or leg (based
NIHSS Q5, 6, 7, 8, 9 > 0). For this subgroup analysis in
addition to comparing their overall functional
outcome based on the ordinal analysis of mRS, we will
compare with Motor score, and Physical function
scores based on the SIS domains described above.
8. In patients with aphasia at randomisation, does
fluoxetine improve communication? Patients with
aphasia (based on NIHSS Q9 > 0). For this subgroup,
analysis in addition to comparing their overall
functional outcome based on mRS based on ordinal
analysis we will compare with SIS – communication
subscale.
For questions 7 and 8, because patients may have a
combination of neurological deficits, individual
patients may appear in more than one subgroup.
9. Is there a relationship between functional status at
six months and mood and is this relationship
affected by fluoxetine? We will perform exploratory
analyses of potential mediating factors, e.g. the role
of depression. These will not be reported in the
primary publication. We will seek to answer the
question whether any benefits are mediated by
improvement in mood (based on MHI5 in FOCUS,
PHQ9 in AFFINITY and MADRS in EFFECTS) and
also whether any apparent loss of benefits in mRS or
SIS at 6–12 months is because of a deterioration in
mood.
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Missing data
Our randomisation systems do not allow investigators to
proceed to treatment allocation without entering complete
baseline data (Table 1). The mRS, our primary outcome,
includes death, so it is expected that the number with
missing mRS at follow-up will be minimal. Anyone with
missing mRS will not be included in any analysis requiring
mRS (complete case analysis).
For secondary outcomes where missing data are
expected because data will not be available for patients
who have not survived, we will present results for those
who are alive at follow-up and any discrepancy in death
rates between groups will be taken into account in the
interpretation. Missing data for single questions within
scores will be handled as detailed by each scoring
method, where responses to all questions within a scale
or subscale are missing that patient will not be included
in that part of the analysis. Immediately before database
lock, we will carry out a blinded review of the complete-
ness of primary and secondary outcomes. If we see
higher levels of missing mRS data than expected (> 5%),
we will use a suitable analysis, based on the likely miss-
ing data mechanism. We will consider whether to extend
missing data methods to secondary outcomes. If
required due to number of patients with missing scores,
a sensitivity analysis may be performed.
Protocol deviations, adherence and blinding
Inclusion/Exclusion violations: we will report the number
and percentage of participants randomised who did not
meet the entry criteria, e.g. non-strokes, with exclusion
criteria. However, they will be included in the primary
analysis. A secondary analysis will exclude ineligible
patients (see below).
Unblinding: We will report the number of patients
who required unbinding of study medication during the
trial by treatment arm and where available present the
reasons for unblinding.
Adherence: Each participant is issued with a total of
six months’ supply of trial medication. At six months,
they are asked if they have completed the course and
taken all the capsules and also on average how often
they took capsules. They are asked the reasons for stop-
ping, as well as the date of stopping. Where possible, we
retrieve and count the unused trial medication. Before
unblinding we will derive an estimated date on which
the patient was thought to have taken their last dose of
trial medication and use the interval (days) from first
dose to that date as our main measure of adherence.
This will be based on all of the available information.
We will use a combination of:
a. inclusion/exclusion violations;
b. the answers to the adherence questions (see above);
c. number, percentage and duration of any open label
SSRI intake before the six-month follow-up;
d. the reasons for stopping trial medication
to define several types of non-adherence to the protocol
(see 1-8 below).
A so-called intention-to-treat analysis, where the
outcomes of patients are analysed in the groups they
were randomised to regardless of treatment received,
provides the least biased and most robust evidence of
the effect of treatment. However, the observed treatment
effect may be reduced if a large number of patients are
included who are unlikely to benefit because they did not
have a stroke or more likely where a large proportion of
patients do not receive the allocated treatment or actually
received the alternative treatment (i.e. cross-overs).
If the primary analysis in the individual trials or the
individual patient data meta-analysis does not demon-
strate an improvement of functional outcome (mRS) at
the six-month follow-up, the question will arise whether
this is this likely to be due to poor adherence to the
protocol and/or trial medication? This is important since
we would not wish to abandon a potentially useful treat-
ment simply because of poor adherence to trial proto-
cols or trial medication. These might be improved in any
future trials. We will perform further per protocol ana-
lyses to reassure the clinical community that the trials
have not underestimated any treatment effect to an
extent which would alter future clinical practice or, more
likely, the need for further randomised trials of SSRIs in
stroke.
Inevitably, analyses which try to take account of adher-
ence introduce a degree of patient selection and thus are
likely to introduce bias.
These exploratory sensitivity analyses to account for
non-adherence will include all of the analyses of the
primary outcome and selected secondary outcomes:
 living at home or with relatives vs care home,
hospital or long-term hospital care;
 mRS at six months and 12 months (mRS 0–2 vs
mRS 3–6);
 new diagnosis of depression since randomisation by
six months and 12 months;
 SIS domain scores;
 averaged score over all SIS domains;
 SF36 vitality subscale score;
 utility based on EQ5D-5L and population
preferences.
These analyses will not include any analysis of
subgroups defined on the basis of baseline variables. The
following groups will be sequentially added to the group
excluded from the analyses:
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1. Patients who did not meet the entry critria for the
trial.
2. Patients who did not receive any trial medication.
3. Patients who received < 90 days of trial medication
because of failures in trial procedures, e.g. failures to
transfer trial medication with patients during moves
between hospitals, care homes and home. The
90-day cut-off was chosen because previous trials
have tested this duration of treatment with apparent
benefit [30].
4. Patients who received trial medication for < 90 days
because of patient or relative concerns but not due
to suspected adverse reactions.
5. Patients who received < 90 days of trial medication
because they experienced symptoms which were
attributed to the trial medication.
6. Patients who had been allocated to placebo who
received an SSRI (fluoxetine or other) within the
first 90 days and which was not known to have been
stopped within ten days of starting.
7. Patients who had been allocated to fluxoetine who
received an SSRI (fluoxetine or other) within the
first 90 days and which was not known to have been
stopped within ten days of starting.
8. Patients who did not complete at least 150 days of
treatment. We chose this cut-off because patients
sometimes received the questionnaires shortly before
six months and some stopped the trial medication at
that point, while others finished off the 186 capsules.
We regarded both as fully adherent.
Individual patient data meta-analysis
This will allow us: to provide the most precise estimates of
any risks and benefits; to detect reliably a smaller overall
effect size than those detectable by the individual trials; to
better determine the effects of fluoxetine vs placebo in
subgroups; and to broaden the generalisability of the
results. It also provides the best opportunity to determine
whether any combinations of baseline characteristics might
be associated with larger treatment effects. Also, it aims to
identify where the treatment effect differs between studies
since we hypothesise that characteristics of the healthcare
systems in which the trials were performed and the trial
processes which were tailored to the local healthcare
systems may influence the treatment effect. For instance:
 the method of dispensing, prescribing and
optimising adherence to the trial medication differs
between the trials;
 the location, intensity and duration of rehabilitation
differs between healthcare systems;
 whether patients with depression were included in
the study (as in FOCUS and AFFINITY) or not (as
in EFFECTS).
Before performing analyses of estimated treatment
effects (see below), we will perform descriptive and
exploratory analyses to identify and display differences
in baseline characteristics between the types of patient
enrolled in the three trials; specifically, statistical com-
parisons of baseline means (using t-tests) and prevalence
(using chi-squared tests) between patients enrolled in
the three trials. Also, we will describe the duration and
type of hospital stays between randomisation and
discharge home, discharge to a residential or nursing
home, or death. The reason for carrying out these initial
analyses is to aid the interpretation of any apparent
between-trial treatment differences that may be identified.
The individual patient data meta-analysis will include all
of the analyses described for the individual trials, including
the same subgroup analyses, on the combined dataset. All
regression models (linear, logistic, Cox proportional
hazards) will be meta-analysed across trials using a ‘two-
stage’ approach. ‘The first stage will be to perform the
ordinal logistic, logistic and Cox proportional hazards
regressions separately for each trial, as described for the
main within-trial analysis. The second stage will take the
point estimate and standard error of the treatment effect
from the within-trial analyses. These will be meta-
analysed using a generic inverse variance model. Fixed
effect analyses will be performed and presented.
Trials status
FOCUS recruited its first patient on 10 September 2012
and its last on 31 March 2017, AFFINITY recruited its
first patient on 11 January 2013 and EFFECTS on 20
October 2014. Our target is to complete recruitment
and follow-up in all three trials by 2020.
Additional file
Additional file 1: The draft statisitcal analysis plan written by CG and SL
prior to any unblinding to interim analyses of FOCUS trial. (DOC 978 kb)
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